Management of adverse drug events in TB therapy

European Respiratory Monograph

Volumn 58, Issue , 2012, Pages 167-193

  Leung, Chi Chiu ^a   Daley, Charles L ^b   Rieder, Hans L ^c,d   Yew, Wing Wai ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b DEPARTMENT OF MEDICINE   (United States)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Adverse reaction; Anti tuberculosis drugs; Drug interaction; Management

Indexed keywords

EID: 84870846479     PISSN: 1025448X     EISSN: 20756674     Source Type: Book Series    
DOI: 10.1183/1025448x.10023611     Document Type: Article

References (134)

1. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477.
2. Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis 2007; 11: 868-875.
3. Chang KC, Leung CC, Tam CM. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis 2004; 8: 1492-1498.
4. Tekle B, Mariam DH, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi zone in Ethiopia. Int J Tuberc Lung Dis 2002; 6: 573-579.
5. Fry RS, Khoshnood K, Vdovichenko E, et al. Barriers to completion of tuberculosis treatment among prisoners in St. Petersburg, Russia. Int J Tuberc Lung Dis 2005; 9: 1027-1033.
6. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth global report. The WHO/ IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2008.394. Geneva, WHO, 2008.
7. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
8. Torun T, Gungor O, Ozmen I, et al. Side effects associated with the treatment of multi-drug resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
9. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualized treatment of multi-drug resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
10. Harries AD, Zachariah R, Lawn SD. Providing HIV care for co-infected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 2009; 13: 6-16.
11. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV co-infected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
12. Mori T, Leung CC. Tuberculosis in the global aging population. Infect Dis Clin North Am 2010; 24: 751-768.
13. World Health Organization. Treatment of tuberculosis: guidelines. 4th Edn. WHO/HTM/TB/2009.420. Geneva, WHO, 2010.
14. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis - Emergency Update 2008. WHO/HTM/TB/2008.402. Geneva, World Health Organization, 2008.
15. American Thoracic Society, Centers for Disease Control, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
16. British National Formulary. London, BMJ Group and RPS Publishing, 2009.
17. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982; 23: 56-74.
18. British Thoracic Society. A controlled trial of 6-months' chemotherapy in pulmonary tuberculosis. Final report: Results during the 36-months after the end of chemotherapy and beyond. Br J Dis Chest 1984; 78: 330-336.
19. Hong Kong Chest Service, British Medical Research Council. Five-year follow-up of a controlled trial of five 6- month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987; 136: 1339-1342.
20. Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council. A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Am Rev Respir Dis 1989; 139: 871-876.
21. Hong Kong Chest Service, British Medical Research Council. Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Results at 30 months. Am Rev Respir Dis 1991; 143: 700-706.
22. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalised for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-2030.
23. Døssing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996; 77: 335-340.
24. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-1079.
25. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11: 699-707.
26. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-952.
27. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008; 23: 192-202.
28. Lawrence Flick Memorial Tuberculosis Clinic. Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents. Philadelphia, Philadelphia Tuberculosis Control Program, 1998.
29. Ho CC, Chen YC, Hu FC, et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by antituberculosis regimens. Clin Infect Dis 2009; 48: 1526-1533.
30. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
31. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000; 117: 744-751.
32. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
33. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
34. Nathanson E, Lambregts-van Weezenbeek C, Rich ML, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12: 1389-1397.
35. Caminero JA. A tuberculosis guide for specialist physicians. Paris, International Union Against Tuberculosis and Lung Disease, 2004.
36. Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26: 312-318.
37. Huang YS. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis druginduced liver injury. Expert Opin Drug Metab Toxicol 2007; 3: 1-8.
38. Huang YS, Chem HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
39. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy: clinical perspectives. Clinica Chimica Acta 2001; 313: 31-36.
40. Korzeniewska-Kosela M, Krysl J, Muller N, et al. Tuberculosis in young adults and the elderly. A prospective comparison study. Chest 1994; 106: 28-32.
41. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: Recommendations for HIV-prevalent and resource-constrained settings. WHO/HTM/ TB/2007.379; WHO/HIV/2007.01. Geneva, WHO, 2007.
42. Franke MF, Robins JM, Mugabo J, et al. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med 2011; 8: e1001029.
43. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-1363.
44. Tabarsi P, Saber-Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009; 12: 14.
45. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196: Suppl. 1, S63-S75.
46. HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 revision. www.who.int/hiv/pub/arv/adult2010/en/index.html Date last accessed: August 30, 2011. Date last updated: 2010.
47. Centers for Disease Control. Tuberculosis (TB). www.cdc.gov/tb/TB_HIV_Drugs/default.htm Date last accessed: August 30, 2011. Date last updated: July 19, 2012.
48. Navas E, Marti{dotless} ́n-Da ́vila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162: 97-99.
49. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-161.
50. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341.
51. Yew WW. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002; 25: 111-133.
52. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28: 419-430.
53. Baciewicz AM, Chrisman CR, Finch CK, et al. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335: 126-136.
54. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
55. Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
56. Smit JJ, Schinkel AH, Oude Elferink RP, et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipids from bile and to liver disease. Cells 1993; 75: 451-462.
57. Haumont M, Magdalou J, Lafaurie C, et al. Phenobarbital inducible UDP-glucuronosyl transferase is responsible for glucuronidation of 39-azido-39- deoxythymidine: characterization of the enzyme in human and rat liver microsomes. Arch Biochem Biophys 1990; 281: 264-270.
58. Burger DM, Meenhorst PL, Koks CH, et al. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993; 37: 1426-1431.
59. Coyne KM, Pozniak AL, Lamorde M, et al. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23: 437-446.
60. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: Suppl. 2, S231-S279.
61. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548.
62. Migliori GB, Raviglione MC, Schaberg T, et al. Tuberculosis management in Europe. Eur Respir J 1999; 14: 978-992.
63. Francis J. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd Edn. www.nationaltbcenter.ucsf.edu/ drtb Date last accessed: September 12, 2011. Date last updated: 2011.
64. Mitnick CD, McGee B, Peloquin CA. Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 2009; 10: 381-401.
65. WHO. Toxicity grading scale for determining the severity of adverse events. In: ICTDR Investigator Manual: Monitoring and reporting of adverse events, Section VIII, appendix 8, pp. 132-135 www.icssc.org/Documents/ Resources/AEManual2003AppendicesFebruary_06_2003%20final.pdf Date last accessed: August 22, 2011.
66. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. http://rsc.tech-res.com/ Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf Date last accessed: August 22, 2011. Date last updated: August 2009.
67. Patel AM, McKeon J. Avoidance and management of adverse reactions to antituberculosis drugs. Drug Saf 1995; 12: 1-25.
68. Crofton J, Horne N, Miller F. Clinical Tuberculosis. London, Macmillan Education Ltd, 1992.
69. Harries A. What are the most common adverse drug events to first-line tuberculosis drugs, and what is the procedure for reintroduction of drugs? In: Frieden T, ed. Toman's Tuberuclosis. 2nd Edn. Geneva, World Health Organization, 2004; pp. 152-158.
70. Holland CL, Malasky C, Ogunkoya A, et al. Rapid oral desensitization to isoniazid and rifampin. Chest 1990; 98: 1518-1519.
71. Matz J, Borish LC, Routes JM, et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 1994; 149: 815-817.
72. Buergin S, Scherer K, Hausermann P, et al. Immediate hypersensitivity to rifampicin in 3 patients: diagnostic procedures and induction of clinical tolerance. Int Arch Allergy Immunol 2006; 140: 20-26.
73. Horne NW, Grant IWB. Development of drug resistance to isoniazid during desensitization: a report of two cases. Tubercle 1963; 44: 180-182.
74. Berte SJ, Dimase JD, Christianson CS. Isoniazid, para-aminosalicylic acid, and streptomycin intolerance in 1,744 patients. An analysis of reactions to single drugs and drug groups plus data on multiple reactions, type and time of reactions, and desensitization. Am Rev Respir Dis 1964; 90: 598-606.
75. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines: diseases characterized by urethritis and cervicitis. Table 1: Oral desensitization protocol for patients with penicillin allergy. www.cdc.gov/std/treatment/2010/urethritis-and-cervicitis.htm#table 1 Date last accessed: January 30, 2011.
76. Thompson JE. Themanagement of hypersensitivity reactions to antituberculosis drugs. Med J Aust 1969; 2: 1058-1063.
77. Peloquin CA, Zhu M, Adam RD, et al. Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions. Ann Pharmacother 2001; 35: 1332-1338.
78. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhoea and colitis. World J Gastroenterol 2009; 15: 1554-1580.
79. Chang KC, Leung CC, Yew WW, et al. Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients. Int J Tuberc Lung Dis 2009; 13: 341-346.
80. Kucers A, Crowe S, Grayson ML, eds. The use of antibiotics. 5th Edn. Oxford, Butterworth Heinemann, 1997.
81. Bennett WM. Aminoglycoside nephrotoxicity. Nephron 1983; 35: 73-77.
82. Shin S, Furin J, Alcantara F, et al. Hypokalaemia among patients receiving treatment for multidrug-resistant tuberculosis. Chest 2004; 125: 974-980.
83. Begg EJ, Barclay ML. Aminoglycosides - 50 years on. Br J Clin Pharmacol 1995; 39: 597-603.
84. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
85. Schaumburg H, Kaplan J, Windebank A, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 1983; 309: 445-448.
86. Schwarz A, Perez-Canto A. Nephrotoxicity of antiinfective drugs. Int J Clin Pharmacol Ther 1998; 36: 164-167.
87. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374.
88. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13: 119-126.
89. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5.
90. Voogt GR, Schoeman HS. Ototoxicity of aminoglycoside drugs in tuberculosis treatment. S Afr J Commun Disord 1996; 43: 3-6.
91. Karnik AM, Al-Shamali MA, Fenech FF. A case of ocular toxicity to ethambutol - an idiosyncratic reaction? Postgrad Med J 1985; 61: 811-813.
92. Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council. A doubleblind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
93. Whittington RM. Fatal hepatotoxicity of antitubercular chemotherapy. Lancet 1991; 338: 1083-1084.
94. Tost JR, Vidal R, Cayla J, et al. Severe hepatotoxicity due to anti-tuberculosis drugs in Spain. Int J Tuberc Lung Dis 2005; 9: 534-540.
95. Orman ES, Conjeevaram HS, Vuppalanchi R, et al. Clinical and histopathologic features of fluoroquinoloneinduced liver injury. Clin Gastroenterol Hepatol 2011; 9: 517-523.
96. Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136.
97. Fernandez-Villar A, Sopena B, Fernandez-Villar J, et al. The influence of risk factors on the severity of antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8: 1499-1505.
98. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
99. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21: 1301-1308.
100. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998; 157: 1871-1876.
101. Ozick LA, Jacob L, Comer GM, et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 1995; 90: 1978-1980.
102. Yildiz A, Sever MS, Turkmen A, et al. Tuberculosis after renal transplantation: experience of one Turkish centre. Nephrol Dial Transplant 1998; 13: 1872-1875.
103. Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation 1999; 68: 1268-1271.
104. Aguado JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain, Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63: 1278-1286.
105. Nolan CM, Sandblom RE, Thummel KE, et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 1994; 105: 408-411.
106. Collins C, Starmer GA. A review of the hepatotoxicity of paracetamol at therapeutic or near-therapeutic dose levels, with particular reference to alcohol abusers. Drug Alcohol Rev 1995; 14: 63-79.
107. Bartelink AK, Lenders JW, van Herwaarden CL, et al. Fatal hepatitis after treatment with isoniazid and rifampicin in a patient on anticonvulsant therapy. Tubercle 1983; 64: 125-128.
108. McNeill L, Allen M, Estrada C, et al. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003; 123: 102-106.
109. Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during anti-tuberculous therapy. Am J Respir Crit Care Med 2012; 185: 653-659.
110. Watkins PB. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis 2009; 29: 393-399.
111. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests? Clin Pharmacol Ther 2009; 85: 331-334.
112. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969; 71: 1113-1120.
113. Mitchell JR, Long MW, Thorgeirsson UP, et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventative therapy. Chest 1975; 68: 181-190.
114. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 2008; 48: 1680-1689.
115. Zimmerman HJ. Drug-induced liver disease. In: Schiff E, ed. Schiff's Diseases of the Liver. Baltimore, Lippincott- Raven, 1999; pp. 973-1064.
116. Ramaiah SK. Preclinical safety assessment: current gaps, challenges, and approaches in identifying translatable biomarkers of drug-induced liver injury. Clin Lab Med 2011; 31: 161-172.
117. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-839.
118. Tahaoglu K, Ataç G, Sevim T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-69.
119. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991; 99: 465-471.
120. Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008; 177: 1391-1396.
121. Yew WW, Lee J, Wong PC, et al. Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction. Int J Clin Pharmacol Res 1992; 12: 173-178.
122. Saigal S, Agarwal SR, Nandeesh HP, et al. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001; 16: 1028-1032.
123. Marra F, Marra CA, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005; 128: 1406-1413.
124. Marra F, Cox VC, Fitz Gerald JM, et al. Successful treatment of multidrug-resistant tuberculosis following druginduced hepatic necrosis requiring liver transplant. Int J Tuberc Lung Dis 2004; 8: 905-909.
125. Farrell FJ, Keeffe EB, Man KM, et al. Treatment of hepatic failure secondary to isoniazid hepatitis with liver transplantation. Dig Dis Sci 1994; 39: 2255-2259.
126. Baniasadi S, Eftekhari P, Tabarsi P, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010; 22: 1235-1238.
127. Holdiness MR. A review of blood dyscrasias induced by the antituberculosis drugs. Tubercule 1987; 68: 301-309.
128. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrugresistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
129. Briasoulis A, Agarwal V, Pierce WJ. QT Prolongation and Torsade de Pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011; 120: 103-110.
130. Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010; 33: 303-314.
131. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167: 2469-2475.
132. Thee S, Zollner EW, Willemse M, et al. Abnormal thyroid function tests in children on ethionamide treatment. Int J Tuberc Lung Dis 2011; 15: 1191-1193.
133. Satti H, Mafukidze A, Jooste PL, et al. High rate of hypothyroidism among patients treated for multidrugresistant tuberculosis in Lesotho. Int J Tuberc Lung Dis 2012; 16: 468-472.
134. Garcia Vidal C, Rodriguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005; 40: 756-759.